Jessica Diekhoff, APRN
Adult Health · St Louis, MONPI 1164662276
Payments from drug & device makers
Across 183 payments — averaging $18.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$376
- Lilly USA, LLC$349
- Pfizer$182
- GSK$146
- Novartis$127
- plus $806 from 18 others
What the payments were for
- Food & beverage$3,359100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 81 | $1,373 |
| Novo Nordisk | 22 | $376 |
| Lilly USA, LLC | 12 | $349 |
| Pfizer | 12 | $182 |
| GSK | 8 | $146 |
| Novartis | 6 | $127 |
| Amgen | 7 | $125 |
| Abbott | 6 | $111 |
| Phathom Pharmaceuticals, Inc. | 2 | $106 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| AstraZeneca | 3 | $54 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $44 |
| Bayer | 3 | $44 |
| Boehringer Ingelheim | 2 | $34 |
| Noven Therapeutics, LLC | 2 | $27 |
| Gilead | 1 | $26 |
| Halozyme Inc | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Ardelyx, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Tris Pharma Inc | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,359 in reported general payments places this provider in the 80th percentile of 555 adult health providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 14 | $23,310 |
| EliquisApixaban | 22 | $21,064 |
| RybelsusSemaglutide | 11 | $18,148 |
| MounjaroTirzepatide | 16 | $16,693 |
| TrulicityDulaglutide | 15 | $15,708 |
| OzempicSemaglutide | 14 | $14,737 |
| MyrbetriqMirabegron | 13 | $11,924 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $3,152 |
| SynthroidLevothyroxine Sodium | 14 | $1,351 |
| Losartan Potassium | 90 | $939 |
| Atorvastatin Calcium | 109 | $647 |
| Ultra-Fine Short Pen NeedlePen Needle, Diabetic | 12 | $610 |
| Gabapentin | 33 | $419 |
| Metoprolol Succinate | 35 | $400 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $376 | $32,88525 claims |
| Lilly USA, LLCMounjaro, Trulicity | $349 | $32,40131 claims |
| Boehringer IngelheimJardiance | $34 | $23,31014 claims |
| PfizerEliquis | $182 | $21,06422 claims |
| AbbVieSynthroid | $1,373 | $1,35114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 555 adult health providers in Missouri.
Other adult health in St Louis
- Tabitha StithChesterfield$300K
- Stephanie VogelSaint Louis$115K
- Racquel FrisellaChesterfield$110K
- Shannon TuckerSaint Louis$93K
- Laurencia KlipfelSaint Louis$79K
- Maria WallsSaint Louis$69K
- Katie MurrayIndependence$59K
- Patrick BehnkeChesterfield$54K
- Elaine ZobristFenton$38K
- Yolanda Thompson MartinKansas City$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.